References
- Medeiros AA. Evolution and dissemination of beta-lacta-mases accelerated by generations of 13-lactam antibiotics. Clin Infect Dis 1997; 24: S19–45.
- Cantu C, Huang W, Palzkill T. Selection and characteri-zation of amino acid substitution at residues 237-240 of TEM-1 I3-lactamase with altered substrate specificity for aztreonam and ceftazidime. J Biol Chem 1996; 271: 22538–22545.
- Palzkill T, Le Q, Venkatachalam KV, LaRocco M, et al. Evolution of antibiotic resistance: several different amino acid substitutions in an active site loop alter the substrate profile of I3-lactamase. Mol Microbiol 1994; 12: 217–29
- Venkatachalam KV, Huang W, LaRocco M, et al. Characterization of TEM-1 13-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. J Biol Chem 1994; 269: 23444–23450.
- Blazquez J, Morosini MI, Negri MC et al. Selection of naturally occurring extended-spectrum TEM 13-lactamase vari-ants by fluctuating 13-lactam pressure. Antimicrob Agents Chemother 2000; 44: 2182–2184.
- Negri MC, Lipsitich M, Blazquez J et al. Concentration-dependent selection of small phenotypic differences in TEMP-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother 2000; 44: 2485–2491.
- Barlow M, Hall BC. Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the TEM I3-lactamase. Genetics 2002; 160: 823–832.
- Perilli M, Segatore B, Franceschini N, et al. Ceftibuten stability to active-site serine and metallo-I3-lactamases. Intern J Antimicrob Agents 2001; 17: 45–50.
- Kitzis MD, Liassine N, Ferrê B, et al. In vitro activity of 15 oral 13-lactams against Klebsiella pneumoniae harboring new extended-spectrum I3-lactamases. Antimicrob Agents Chemother 1990; 34: 1783–1786.
- Jacoby GA, Carreras I. Activities of 13-lactam antibiotics against Escherichia coli strains producing extended-spectrum 13-lactamases. Antimicrob Agents Chemother 1990; 34: 858–862.
- Liao CH, Sheng WH, Wang JT, et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum P-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 2006; 39: 59–66.
- Tavío MM., Vila J., Ruiz J, et al. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother 1999; 44: 735-742
- Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. CLSI docu-ment M100-515. Clinical and Laboratory Standards Institute. Wayne, PA, USA. 2005.